Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection.
A 45-year-old woman with HIV infection presented with thrombotic microangiopathy 1 week after initiating therapy with the nucleoside analogue abacavir. She was successfully treated with plasmapheresis and corticosteroids.
Department of Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA.
Adam J
AJ
Olszewski
Janet M
JM
Shapiro
D019380:Anti-HIV Agents / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001772:Blood Cell Count; D001806:Blood Urea Nitrogen; D018791:CD4 Lymphocyte Count; D003404:Creatinine / Q000097:blood; D003422:Critical Care / Q000379:methods; D015224:Dideoxynucleosides / Q000009:adverse effects*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006242:Haptoglobins / Q000378:metabolism; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008875:Middle Aged; D010956:Plasmapheresis; D010976:Platelet Count; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D016896:Treatment Outcome; D000099227:Abacavir
D019380:Anti-HIV Agents; D000893:Anti-Inflammatory Agents; D001219:Aspartate Aminotransferases; D001663:Bilirubin; D003404:Creatinine; D015224:Dideoxynucleosides; D005338:Fibrin Fibrinogen Degradation Products; D006242:Haptoglobins; D016756:Immunoglobulins, Intravenous; D007770:L-Lactate Dehydrogenase; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C036309:fibrin fragment D